<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079793</url>
  </required_header>
  <id_info>
    <org_study_id>SCCC-09809</org_study_id>
    <secondary_id>CDR0000666842</secondary_id>
    <nct_id>NCT01079793</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery</brief_title>
  <official_title>A Phase I/II Study of Adjuvant Prostate Irradiation and Ixabepilone For High Risk Prostate Cancer Post-Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Ixabepilone may also make&#xD;
      tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy&#xD;
      after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when&#xD;
      given together with radiation therapy to see how well it works in treating patients with&#xD;
      high-risk stage III prostate cancer after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum-tolerated dose and dose-limiting toxicity of ixabepilone in&#xD;
           combination with concurrent intensity-modulated radiation therapy in patients with&#xD;
           high-risk prostate cancer after prostatectomy. (Phase I)&#xD;
&#xD;
        -  To determine the toxicity profile of this regimen in these patients. (Phase I)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess freedom from progression in patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  To assess biochemical failure, local failure, and distant failure in patients treated&#xD;
           with this regimen. (Phase II)&#xD;
&#xD;
        -  To assess disease-specific survival and overall survival of patients treated with this&#xD;
           regimen. (Phase II)&#xD;
&#xD;
        -  To evaluate acute and late toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of ixabepilone followed by a phase II&#xD;
      study.&#xD;
&#xD;
      Patients undergo adjuvant intensity-modulated radiation therapy once daily, 5 days a week,&#xD;
      for 7-9 weeks. Patients also receive concurrent ixabepilone IV over 1 hour on days 1 and 8.&#xD;
      Treatment with ixabepilone repeats every 21 days for 3 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 1 year, every&#xD;
      6 months for 3 years, and then annually for 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Overlapping study, PI preferred to enroll in alternate trial.&#xD;
  </why_stopped>
  <start_date type="Actual">May 26, 2010</start_date>
  <completion_date type="Actual">October 17, 2011</completion_date>
  <primary_completion_date type="Actual">October 17, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (phase I)</measure>
    <time_frame>3 years</time_frame>
    <description>Dose-limiting toxicity (phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose (phase I)</measure>
    <time_frame>3 years</time_frame>
    <description>Maximum-tolerated dose (phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from progression for 3 years (phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Freedom from progression for 3 years (phase II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical, local and distant failure (phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Time to biochemical, local and distant failure (phase II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Disease-specific survival (phase II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate (phase II)</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate (phase II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as assessed by NCI CTCAE v. 4.0</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events as assessed by NCI CTCAE v. 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ixabepilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <arm_group_label>ixabepilone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>ixabepilone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <arm_group_label>ixabepilone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
               -  Must have undergone any common form of prostatectomy (e.g., open, perineal,&#xD;
                  laparoscopic, or robotic) within the past 2 years&#xD;
&#xD;
               -  T3 disease or positive surgical margins&#xD;
&#xD;
               -  Node negative (N0) and free of distant metastasis (M0) by a bone scan and CT scan&#xD;
                  or MRI of the pelvis within the past 90 days&#xD;
&#xD;
               -  Considered high-risk disease&#xD;
&#xD;
          -  Gleason score = 7 and post-operative PSA &gt; 0 and ≤ 2 ng/mL OR Gleason score ≥ 8 and&#xD;
             post-operative PSA ≥ 0 and ≤ 2 ng/mL&#xD;
&#xD;
          -  Pre-prostatectomy PSA available&#xD;
&#xD;
               -  Range of pre-prostatectomy PSA values not required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod (ECOG) performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times ULN&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Patients with urinary incontinence waiting for stabilization of urinary function after&#xD;
             prostatectomy allowed for up to 6 months&#xD;
&#xD;
          -  No CTCv4 peripheral neuropathy (motor or sensory) ≥ grade 1&#xD;
&#xD;
          -  No history of inflammatory colitis including Crohn disease or ulcerative colitis&#xD;
&#xD;
          -  No significant history of psychiatric illness&#xD;
&#xD;
          -  No other invasive malignancy within the past 3 years except adequately treated&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the oral cavity&#xD;
&#xD;
          -  No severe, active co-morbidity with any of the following:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the past 6 months&#xD;
&#xD;
               -  Transmural myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring IV antibiotics&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days&#xD;
&#xD;
               -  Immunocompromised patients or AIDS based upon current CDC definition&#xD;
&#xD;
                    -  HIV testing not required&#xD;
&#xD;
          -  No history of hypersensitivity reactions to agents containing Cremophor® EL or its&#xD;
             derivatives (e.g., polyoxyethylated castor oil)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior pelvic radiotherapy or radiotherapy for another malignancy that encompasses ≥&#xD;
             30% of major bone marrow-containing areas (e.g., pelvis or lumbar spine)&#xD;
&#xD;
          -  No prior hormonal therapy for prostate cancer&#xD;
&#xD;
               -  Prior hormonal agents, e.g., finasteride or dutasteride, for benign prostatic&#xD;
                  hypertrophy allowed&#xD;
&#xD;
          -  No other concurrent adjuvant antineoplastic therapy planned while on this protocol,&#xD;
             including the following:&#xD;
&#xD;
               -  Cryotherapy&#xD;
&#xD;
               -  Hormonal therapy&#xD;
&#xD;
               -  Other chemotherapy for prostate cancer&#xD;
&#xD;
                    -  Prior chemotherapy for a different type of cancer allowed provided it was&#xD;
                       administered &gt; 3 years ago&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Pistenmaa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

